Lacidipine Zentiva

Lacidipine, the active ingredient in Lacidipine Zentiva, is a calcium channel blocker presented as an oral tablet for oral use. It is used to treat hypertension in adult patients by lowering elevated blood pressure.

GNH USA supplies Lacidipine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine is a dihydropyridine calcium channel blocker indicated for the management of high blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure, helping to achieve target levels and lower cardiovascular risk.

Lacidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Hepatic injury: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis. - Angio‑edema: swelling of face, lips, or throat. - Arrhythmias: abnormal heart rhythms.

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: check baseline and follow‑up readings to avoid excessive hypotension. - Hepatic function: use caution in patients with liver impairment and adjust therapy if needed. - Elderly patients: start at the lowest effective dose and monitor for dizziness. - Concomitant antihypertensives: assess risk of additive blood‑pressure lowering effects. - Discontinuation: avoid abrupt withdrawal; taper if long‑term therapy is stopped. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase lacidipine plasma levels. - Other potent antihypertensives (e.g., ACE inhibitors, ARBs): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lacidipine effectiveness. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): additive cardiovascular effects. - Grapefruit juice: can increase drug exposure. - NSAIDs: may blunt antihypertensive response. - Diuretics: may enhance orthostatic hypotension.